300238 冠昊生物
已收盘 07-22 15:00:00
资讯
新帖
简况
冠昊生物最新公告:控股股东广东知光部分股份可能被司法强制执行
证券之星 · 07-19 18:30
冠昊生物最新公告:控股股东广东知光部分股份可能被司法强制执行
冠昊生物:截止2024年7月10日,公司股东总户数为32054
证券之星 · 07-17
冠昊生物:截止2024年7月10日,公司股东总户数为32054
冠昊生物:截止2024年6月28日,公司股东总户数为32823
证券之星 · 07-02
冠昊生物:截止2024年6月28日,公司股东总户数为32823
干细胞概念盘中跳水,冠昊生物跌0.78%
自选股智能写手 · 07-01
干细胞概念盘中跳水,冠昊生物跌0.78%
冠昊生物获得实用新型专利授权:“省力式活塞驱动结构”
证券之星 · 06-26
冠昊生物获得实用新型专利授权:“省力式活塞驱动结构”
冠昊生物:截止2024年6月20日,公司股东总户数为32863
证券之星 · 06-24
冠昊生物:截止2024年6月20日,公司股东总户数为32863
冠昊生物:公司研发项目情况请参见公司2023年年度报告中的相关内容
证券之星 · 06-07
冠昊生物:公司研发项目情况请参见公司2023年年度报告中的相关内容
【企业动态】冠昊生物新增1件法院诉讼,案由为建设工程施工合同纠纷
证券之星 · 05-24
【企业动态】冠昊生物新增1件法院诉讼,案由为建设工程施工合同纠纷
冠昊生物(300238)5月23日主力资金净卖出2154.58万元
证券之星 · 05-23
冠昊生物(300238)5月23日主力资金净卖出2154.58万元
冠昊生物:截止2024年5月10日,公司股东总户数为39688
证券之星 · 05-17
冠昊生物:截止2024年5月10日,公司股东总户数为39688
冠昊生物(300238)5月10日股东户数3.97万户,较上期增加28.74%
证券之星 · 05-17
冠昊生物(300238)5月10日股东户数3.97万户,较上期增加28.74%
冠昊生物(300238)5月15日主力资金净卖出1097.30万元
证券之星 · 05-15
冠昊生物(300238)5月15日主力资金净卖出1097.30万元
冠昊生物:目前公司不涉及合成生物业务及相关研究
证券之星 · 05-09
冠昊生物:目前公司不涉及合成生物业务及相关研究
冠昊生物最新公告:公司不涉及合成生物业务及相关研究
证券之星 · 05-09
冠昊生物最新公告:公司不涉及合成生物业务及相关研究
冠昊生物(300238.SZ)不涉及合成生物业务及相关研究
智通财经 · 05-09
冠昊生物(300238.SZ)不涉及合成生物业务及相关研究
概念掘金 | 逆势大爆发!细胞免疫治疗概念“异军突起”,市场前景几何?
格隆汇 · 05-08
概念掘金 | 逆势大爆发!细胞免疫治疗概念“异军突起”,市场前景几何?
冠昊生物涨19.96%,西南证券一个月前给出“买入”评级
证券之星 · 05-08
冠昊生物涨19.96%,西南证券一个月前给出“买入”评级
冠昊生物(300238)4月30日股东户数3.08万户,较上期减少1.74%
证券之星 · 05-07
冠昊生物(300238)4月30日股东户数3.08万户,较上期减少1.74%
冠昊生物最新公告:一季度净利1439.15万元 同比减少34.92%
证券之星 · 04-26
冠昊生物最新公告:一季度净利1439.15万元 同比减少34.92%
图解冠昊生物一季报:第一季度单季净利润同比减34.92%
证券之星 · 04-26
图解冠昊生物一季报:第一季度单季净利润同比减34.92%
加载更多
公司概况
公司名称:
冠昊生物科技股份有限公司
所属行业:
专用设备制造业
上市日期:
2011-07-06
主营业务:
冠昊生物科技股份有限公司是一家从事再生医学材料及再生型医用植入器械研发、生产及销售的高科技企业。公司主要从事研究、开发、生产:Ⅱ类、Ⅲ类:6846植入材料和人工器官,6846医用卫生材料及敷料;销售自产产品及提供服务;三类、二类:植入材料和人工器官,医用卫生材料及敷料的批发、零售。公司的技术研究和产品开发紧跟国家发展方向,目前公司参与了两项“十三五”国家重点研发计划,均是围绕组织修复与可再生材料进行技术创新和新产品开发。
发行价格:
18.20
{"stockData":{"symbol":"300238","market":"SZ","secType":"STK","nameCN":"冠昊生物","latestPrice":8.53,"timestamp":1721631810000,"preClose":8.9,"halted":0,"volume":8639994,"delay":0,"floatShares":265000000,"shares":265000000,"eps":0.0879,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.37,"latestTime":"07-22 15:00:00","open":8.75,"high":8.77,"low":8.09,"amount":73369500,"amplitude":0.0764,"askPrice":8.54,"askSize":161,"bidPrice":8.53,"bidSize":68,"shortable":0,"etf":0,"ttmEps":0.0879,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721698200000},"adr":0,"adjPreClose":8.9,"symbolType":"stock","openAndCloseTimeList":[[1721611800000,1721619000000],[1721624400000,1721631600000]],"highLimit":9.79,"lowLimit":8.01,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":265155701,"pbRate":4.41,"roa":"--","roe":"2.73%","epsLYR":0.12,"committee":0.29783,"marketValue":2262000000,"floatMarketCap":2262000000,"peRate":97.042096,"changeRate":-0.0416,"turnoverRate":0.0326,"status":1},"requestUrl":"/m/hq/s/300238","defaultTab":"news","newsList":[{"id":"2452742504","title":"冠昊生物最新公告:控股股东广东知光部分股份可能被司法强制执行","url":"https://stock-news.laohu8.com/highlight/detail?id=2452742504","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452742504?lang=zh_cn&edition=full","pubTime":"2024-07-19 18:30","pubTimestamp":1721385017,"startTime":"0","endTime":"0","summary":"冠昊生物公告,公司收到控股股东广东知光生物科技有限公司(“广东知光”)《告知函》,获悉广东知光近日收到《广东省广州市荔湾区人民法院执行裁定书》,申请执行人为何莉,被执行人为广东知光生物科技有限公司。公司控股股东广东知光表示,其所持有的公司部分股份存在被司法强制执行而发生变动的可能。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071900042109.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300238","BK0042","BK0046","BK0077","BK0251","BK0086"],"gpt_icon":0},{"id":"2452613996","title":"冠昊生物:截止2024年7月10日,公司股东总户数为32054","url":"https://stock-news.laohu8.com/highlight/detail?id=2452613996","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452613996?lang=zh_cn&edition=full","pubTime":"2024-07-17 18:04","pubTimestamp":1721210647,"startTime":"0","endTime":"0","summary":"证券之星消息,冠昊生物07月17日在投资者关系平台上答复投资者关心的问题。根据《深圳证券交易所创业板股票上市规则》,创业板上市公司半年报业绩预告不属于强制性披露信息,公司严格按照上市规则等相关法律法规要求履行信息披露义务。关于公司2024年半年度经营情况,敬请关注公司后续披露的半年度报告。截止2024年7月10日,公司股东总户数为32054。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071700037564.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300238","BK0251","BK0086","BK0042","BK0077","BK0046"],"gpt_icon":0},{"id":"2448958132","title":"冠昊生物:截止2024年6月28日,公司股东总户数为32823","url":"https://stock-news.laohu8.com/highlight/detail?id=2448958132","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448958132?lang=zh_cn&edition=full","pubTime":"2024-07-02 19:01","pubTimestamp":1719918103,"startTime":"0","endTime":"0","summary":"证券之星消息,冠昊生物(300238)07月02日在投资者关系平台上答复投资者关心的问题。投资者:请问,2024年6月28日收盘,贵司的股东人数是多少?谢谢!冠昊生物董秘:尊敬的投资者您好!截止2024年6月28日,公司股东总户数为32823。感谢您的关注与支持!以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070200029106.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","BK0086","BK0042","BK0046","300238","BK0077"],"gpt_icon":0},{"id":"2448322931","title":"干细胞概念盘中跳水,冠昊生物跌0.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2448322931","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448322931?lang=zh_cn&edition=full","pubTime":"2024-07-01 10:11","pubTimestamp":1719799871,"startTime":"0","endTime":"0","summary":"07月01日,干细胞概念盘中跳水,截至10点11分,干细胞概念整体指数下跌1.02%,报658.100点。从个股上来看,该概念的成分股中,冠昊生物跌0.78%,中源协和、南京新百、华邦健康跌幅居前。从资金上来看,截止发稿,干细胞概念主力净流入为-1282.23万,其中中源协和受到资金热捧,主力净流入305.42万;拉长时间线来看,该板块近20日主力资金净流入-13.55亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240701101111941f2927&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240701101111941f2927&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0077","BK0188","BK0042","BK0216","BK0251","600645","BK0086","BK0046","300238","BK0239"],"gpt_icon":0},{"id":"2446787849","title":"冠昊生物获得实用新型专利授权:“省力式活塞驱动结构”","url":"https://stock-news.laohu8.com/highlight/detail?id=2446787849","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446787849?lang=zh_cn&edition=full","pubTime":"2024-06-26 02:56","pubTimestamp":1719341764,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示冠昊生物新获得一项实用新型专利授权,专利名为“省力式活塞驱动结构”,专利申请号为CN202322967610.6,授权日为2024年6月11日。螺杆具有拨块;拨块插接于插孔,并与联动回转结构联动连接;螺杆能够相对于联动回转结构转动,以使拨块能够转动至与轴向回退联动限位台相互轴向限位的位置处。今年以来冠昊生物新获得专利授权1个,与去年同期持平。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062600004360.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","BK0086","BK0077","BK0042","300238","BK0046"],"gpt_icon":0},{"id":"2445029411","title":"冠昊生物:截止2024年6月20日,公司股东总户数为32863","url":"https://stock-news.laohu8.com/highlight/detail?id=2445029411","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445029411?lang=zh_cn&edition=full","pubTime":"2024-06-24 18:04","pubTimestamp":1719223471,"startTime":"0","endTime":"0","summary":"证券之星消息,冠昊生物(300238)06月24日在投资者关系平台上答复投资者关心的问题。投资者:请问截止到2024年6月20日股东户数是多少?谢谢冠昊生物董秘:尊敬的投资者您好!截止2024年6月20日,公司股东总户数为32863。感谢您的关注与支持!以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062400026255.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","BK0046","BK0086","300238","BK0042","BK0077"],"gpt_icon":0},{"id":"2441053165","title":"冠昊生物:公司研发项目情况请参见公司2023年年度报告中的相关内容","url":"https://stock-news.laohu8.com/highlight/detail?id=2441053165","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441053165?lang=zh_cn&edition=full","pubTime":"2024-06-07 18:03","pubTimestamp":1717754589,"startTime":"0","endTime":"0","summary":"证券之星消息,冠昊生物06月07日在投资者关系平台上答复投资者关心的问题。投资者:请问贵公司最近多年,年销售额4亿左右,是市场饱和了吗?公司核心业务为材料、药业、细胞三大业务板块,各业务板块的市场情况请参见公司近年来的定期报告。公司研发项目情况请参见公司2023年年度报告中的相关内容。感谢您的关注与支持!","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060700036993.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300238","BK0251","BK0086","BK0042","BK0077","BK0046"],"gpt_icon":0},{"id":"2437712729","title":"【企业动态】冠昊生物新增1件法院诉讼,案由为建设工程施工合同纠纷","url":"https://stock-news.laohu8.com/highlight/detail?id=2437712729","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437712729?lang=zh_cn&edition=full","pubTime":"2024-05-24 05:56","pubTimestamp":1716501382,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示,5月10日冠昊生物(300238)新增1件法院诉讼如下:案号:(2024)粤01民终13578号法院:广东省广州市中级人民法院案由:建设工程施工合同纠纷原告:广州市坤龙建筑安装工程有限公司被告:广东益安人防工程科技有限公司、冠昊生物科技股份有限公司案件类型:民事立案日期:2024年5月10日数据来源:企查查以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052400010234.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","BK0046","BK0086","300238","BK0042","BK0077"],"gpt_icon":0},{"id":"2437881267","title":"冠昊生物(300238)5月23日主力资金净卖出2154.58万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2437881267","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437881267?lang=zh_cn&edition=full","pubTime":"2024-05-23 15:29","pubTimestamp":1716449364,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年5月23日收盘,冠昊生物报收于10.37元,下跌4.51%,换手率5.54%,成交量14.69万手,成交额1.54亿元。5月23日的资金流向数据方面,主力资金净流出2154.58万元,占总成交额13.99%,游资资金净流出838.36万元,占总成交额5.44%,散户资金净流入2992.94万元,占总成交额19.43%。冠昊生物主营业务:生产和销售医疗器械、药品及提供细胞技术服务等。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052300023158.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","BK0077","BK0046","300238","BK0042","BK0086"],"gpt_icon":0},{"id":"2436917549","title":"冠昊生物:截止2024年5月10日,公司股东总户数为39688","url":"https://stock-news.laohu8.com/highlight/detail?id=2436917549","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2436917549?lang=zh_cn&edition=full","pubTime":"2024-05-17 18:03","pubTimestamp":1715940188,"startTime":"0","endTime":"0","summary":"证券之星消息,冠昊生物05月17日在投资者关系平台上答复投资者关心的问题。投资者:请问截止到5月10日股东人数是多少?截止2024年5月10日,公司股东总户数为39688。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051700035825.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0042","BK0077","BK0086","BK0251","300238"],"gpt_icon":0},{"id":"2436299568","title":"冠昊生物(300238)5月10日股东户数3.97万户,较上期增加28.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2436299568","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2436299568?lang=zh_cn&edition=full","pubTime":"2024-05-17 17:03","pubTimestamp":1715936597,"startTime":"0","endTime":"0","summary":"证券之星消息,近日冠昊生物披露,截至2024年5月10日公司股东户数为3.97万户,较4月30日增加8859.0户,增幅为28.74%。在医疗器械行业个股中,冠昊生物股东户数高于行业平均水平,截至5月10日,医疗器械行业平均股东户数为2.09万户。从股价来看,2024年4月30日至2024年5月10日,冠昊生物区间涨幅为19.86%,在此期间股东户数增加8859.0户,增幅为28.74%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051700031234.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300238","BK0251","BK0042","BK0086","BK0077"],"gpt_icon":0},{"id":"2435688213","title":"冠昊生物(300238)5月15日主力资金净卖出1097.30万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2435688213","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435688213?lang=zh_cn&edition=full","pubTime":"2024-05-15 15:28","pubTimestamp":1715758137,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年5月15日收盘,冠昊生物报收于10.97元,下跌2.66%,换手率5.47%,成交量14.5万手,成交额1.59亿元。近5日资金流向一览见下表:该股主要指标及行业内排名如下:冠昊生物2024年一季报显示,公司主营收入9144.13万元,同比下降18.85%;归母净利润1439.15万元,同比下降34.92%;扣非净利润1396.71万元,同比下降29.18%;负债率31.88%,投资收益-12.9万元,财务费用13.39万元,毛利率78.05%。冠昊生物主营业务:生产和销售医疗器械、药品及提供细胞技术服务等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051500022547.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","BK0086","BK0042","BK0046","300238","BK0077"],"gpt_icon":0},{"id":"2434122064","title":"冠昊生物:目前公司不涉及合成生物业务及相关研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2434122064","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434122064?lang=zh_cn&edition=full","pubTime":"2024-05-09 18:02","pubTimestamp":1715248951,"startTime":"0","endTime":"0","summary":"证券之星消息,冠昊生物(300238)05月09日在投资者关系平台上答复投资者关心的问题。投资者:董秘您好,请问公司生物新材料与细胞技术领域里的产品能用于下游的生物合成吗?请简单科普一下,谢谢冠昊生物董秘:尊敬的投资者您好!目前公司不涉及合成生物业务及相关研究。感谢您的关注与支持!以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050900032809.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0086","BK0042","BK0251","BK0046","BK0077","300238"],"gpt_icon":0},{"id":"2434063031","title":"冠昊生物最新公告:公司不涉及合成生物业务及相关研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2434063031","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434063031?lang=zh_cn&edition=full","pubTime":"2024-05-09 16:40","pubTimestamp":1715244013,"startTime":"0","endTime":"0","summary":"冠昊生物发布股价异动公告,公司股票于2024年5月7日、5月8日、5月9日连续三个交易日收盘价格涨幅偏离值累计达到30%,属于股票交易异常波动的情形。公司关注到部分媒体、股吧等平台讨论合成生物学及相关热点概念。目前公司不涉及合成生物业务及相关研究。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050900029430.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300238","BK0042","BK0251","BK0046","BK0086","BK0077"],"gpt_icon":0},{"id":"2434987063","title":"冠昊生物(300238.SZ)不涉及合成生物业务及相关研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2434987063","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434987063?lang=zh_cn&edition=full","pubTime":"2024-05-09 16:35","pubTimestamp":1715243739,"startTime":"0","endTime":"0","summary":"智通财经APP讯,冠昊生物(300238.SZ)公告,公司股票(证券代码:300238,证券简称:冠昊生物)于2024年5月7日、5月8日、5月9日连续三个交易日收盘价格涨幅偏离值累计达到30%,属于股票交易异常波动的情形。公司关注到部分媒体、股吧等平台讨论合成生物学及相关热点概念。目前公司不涉及合成生物业务及相关研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1119247.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300238","BK0251","BK0077","BK0042","BK0086","BK0046"],"gpt_icon":0},{"id":"2433141057","title":"概念掘金 | 逆势大爆发!细胞免疫治疗概念“异军突起”,市场前景几何?","url":"https://stock-news.laohu8.com/highlight/detail?id=2433141057","media":"格隆汇","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433141057?lang=zh_cn&edition=full","pubTime":"2024-05-08 16:31","pubTimestamp":1715157113,"startTime":"0","endTime":"0","summary":"医疗健康产业迎新革新","market":"sg","thumbnail":"https://img3.gelonghui.com/c4331-ad8ec8ad-e4d8-4de9-86be-fd28b8d03c4c.jpg?guru_height=852&guru_width=1280","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/c4331-ad8ec8ad-e4d8-4de9-86be-fd28b8d03c4c.jpg?guru_height=852&guru_width=1280"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/727669","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK0251","BK0042","BK1161","BK1574","BK0168","000518","BK0188","BK0201","BK0046","BK0239","BK0135","06978","600645","BK0020","BK0224","BK0216","BK0145","300272","BK0086","BK0077","300813","300238","BK0150","603222"],"gpt_icon":0},{"id":"2433271115","title":"冠昊生物涨19.96%,西南证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2433271115","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433271115?lang=zh_cn&edition=full","pubTime":"2024-05-08 16:22","pubTimestamp":1715156569,"startTime":"0","endTime":"0","summary":"今日冠昊生物涨19.96%,收盘报12.8元。2024年3月11日,西南证券研究员杜向阳发布了对冠昊生物的研报《本维莫德较快增长,生物材料新产品快速放量》,该研报对冠昊生物给出“买入”评级。公司本维莫德有望迎来快速增长,细胞技术服务和生物材料新产品贡献增量。维持“买入”评级。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为西南证券的杜向阳。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050800027431.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600369","300238"],"gpt_icon":0},{"id":"2433722913","title":"冠昊生物(300238)4月30日股东户数3.08万户,较上期减少1.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2433722913","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433722913?lang=zh_cn&edition=full","pubTime":"2024-05-07 17:06","pubTimestamp":1715072766,"startTime":"0","endTime":"0","summary":"证券之星消息,近日冠昊生物披露,截至2024年4月30日公司股东户数为3.08万户,较4月10日减少546.0户,减幅为1.74%。在医疗器械行业个股中,冠昊生物股东户数高于行业平均水平,截至4月30日,医疗器械行业平均股东户数为2.09万户。从股价来看,2024年4月10日至2024年4月30日,冠昊生物区间涨幅为1.29%,在此期间股东户数减少546.0户,减幅为1.74%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050700028483.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300238","BK0077","BK0251","BK0086","BK0046","BK0042"],"gpt_icon":0},{"id":"2430226699","title":"冠昊生物最新公告:一季度净利1439.15万元 同比减少34.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430226699","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430226699?lang=zh_cn&edition=full","pubTime":"2024-04-26 17:48","pubTimestamp":1714124900,"startTime":"0","endTime":"0","summary":"冠昊生物公布2024年第一季度报告,报告期内营业收入为9144.13万元,同比减少18.85%;归属于上市公司股东的净利润1439.15万元,同比减少34.92%;归属于上市公司股东的扣除非经常性损益的净利润1396.71万元,同比减少29.18%,基本每股收益0.05元。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042600042248.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300238","BK0251","BK0077","BK0042","BK0046","BK0086"],"gpt_icon":0},{"id":"2430743237","title":"图解冠昊生物一季报:第一季度单季净利润同比减34.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430743237","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430743237?lang=zh_cn&edition=full","pubTime":"2024-04-26 01:57","pubTimestamp":1714067825,"startTime":"0","endTime":"0","summary":"证券之星消息,冠昊生物2024年一季报显示,公司主营收入9144.13万元,同比下降18.85%;归母净利润1439.15万元,同比下降34.92%;扣非净利润1396.71万元,同比下降29.18%;负债率31.88%,投资收益-12.9万元,财务费用13.39万元,毛利率78.05%。财报数据概要请见下图: 以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042600002679.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300238"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2011-07-06","address":"广东省广州市黄埔区玉岩路12号","stockEarnings":[{"period":"1week","weight":-0.0198},{"period":"1month","weight":-0.0661},{"period":"3month","weight":0.0056},{"period":"6month","weight":-0.2626},{"period":"1year","weight":-0.3697},{"period":"ytd","weight":-0.3437}],"companyName":"冠昊生物科技股份有限公司","boardCode":"AI0035","perCapita":"8271股","boardName":"专用设备制造业","registeredCapital":"26515万元","compareEarnings":[{"period":"1week","weight":0.0037},{"period":"1month","weight":-0.0118},{"period":"3month","weight":-0.0271},{"period":"6month","weight":0.053},{"period":"1year","weight":-0.0591},{"period":"ytd","weight":0.0025}],"survey":" 冠昊生物科技股份有限公司是一家从事再生医学材料及再生型医用植入器械研发、生产及销售的高科技企业。公司主要从事研究、开发、生产:Ⅱ类、Ⅲ类:6846植入材料和人工器官,6846医用卫生材料及敷料;销售自产产品及提供服务;三类、二类:植入材料和人工器官,医用卫生材料及敷料的批发、零售。公司的技术研究和产品开发紧跟国家发展方向,目前公司参与了两项“十三五”国家重点研发计划,均是围绕组织修复与可再生材料进行技术创新和新产品开发。","serverTime":1721632864196,"listedPrice":18.2,"stockholders":"32054人(较上一季度减少2.34%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"冠昊生物(300238)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供冠昊生物(300238)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"冠昊生物,300238,冠昊生物股票,冠昊生物股票老虎,冠昊生物股票老虎国际,冠昊生物行情,冠昊生物股票行情,冠昊生物股价,冠昊生物股市,冠昊生物股票价格,冠昊生物股票交易,冠昊生物股票购买,冠昊生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"冠昊生物(300238)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供冠昊生物(300238)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}